Acetylated Alpha-MSH Fragment
AC-KPV-NH2 is a stabilised alpha-MSH fragment that repairs the intestinal barrier by restoring tight junction proteins, reduces the gut immune inflammation driving IBD and leaky gut, and also lowers systemic inflammatory cytokines throughout the body. It is the most targeted gut-mucosal anti-inflammatory peptide available, working at both the structural and immune levels simultaneously.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
15 mg
Format
Injectable
Composition
5 mg/ml per ml
AC-KPV-NH2 binds melanocortin receptors (MC1R, MC3R) on intestinal epithelial cells, macrophages, and dendritic cells. This activates cAMP-mediated pathways that suppress NF-κB signalling, reduce pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6), and promote epithelial barrier repair. In mucosal tissue it stimulates tight junction protein expression (claudin, occludin, ZO-1), directly improving intestinal permeability. It also reduces mast cell degranulation and inhibits neutrophil infiltration, providing multi-layered anti-inflammatory protection.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
AC-KPV-NH2 upregulates tight junction proteins that seal the intestinal barrier, directly addressing leaky gut at the molecular level: particularly relevant in IBD, food sensitivity, and post-antibiotic gut damage.
By suppressing NF-κB in intestinal immune cells, AC-KPV-NH2 reduces the chronic inflammatory signalling that drives conditions like Crohn's disease and ulcerative colitis.
Beyond gut effects, systemic administration reduces circulating inflammatory markers relevant in metabolic syndrome, autoimmunity, and post-infectious inflammatory states.
Explore selected publications on AC-KPV-NH2, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Research relevant to AC-KPV-NH2
Publication and key finding
The study reports that this study indicates tht KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD.
Gastroenterology
Evidence type
Preclinical study
Research relevant to AC-KPV-NH2
Publication and key finding
The study reports that histologically, inflammatory infiltrates were significantly reduced in KPV-treated mice, which was confirmed by the significant reduction of MPO activity in colonic tissue after KPV treatment.
Inflammatory bowel diseases
Evidence type
Published research
Research relevant to AC-KPV-NH2
Publication and key finding
The study reports that notably, treatment with 50 μg/mL of KPV restored cell viability and reduced IL-1β secretion disrupted by PM10 exposure.
Tissue & cell
Evidence type
Published research
Research relevant to AC-KPV-NH2
Publication and key finding
The study reports that the anti-inflammatory properties of this peptide are also believed to be cyclic AMP dependent.
The Journal of investigative dermatology
Evidence type
Review
Research relevant to AC-KPV-NH2
Publication and key finding
The study reports that alpha-melanocyte-stimulating hormone (alpha-MSH), a neuroimmunomodulatory peptide of ancient origin, is known to be involved in the control of host responses.
Annals of the New York Academy of Sciences
Combinations used in research protocols where AC-KPV-NH2 complements other compounds.
AC-KPV-NH2 + BPC-157
The complete gut repair stack: KPV addresses immune-mediated mucosal inflammation while BPC-157 drives structural tissue regeneration and angiogenesis.
View BPC-157AC-KPV-NH2 + VIP
Layered anti-inflammatory cover: local mucosal action (KPV) combined with systemic cytokine and T-cell modulation (VIP) for broad inflammatory control.
View VIPLabbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
